Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes
In a major trial of more than 17,000 adults with cardiovascular disease and higher body weight, those taking semaglutide had a roughly 20% lower risk of heart attack, stroke, or cardiovascular death
LS can result from mitochondrial tRNA mutations in Cox I, II, III, IV, V, and PDH
One man injected 20 times the correct dose of semaglutide because he misunderstood instructions
PEPTIDE SCIENCES COUPON/DISCOUNT To welcome researchers to our new platform, Peptide Sciences offers exclusive savings opportunities